AN ADAPTIVE, PHASE 2 TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-0670512 FOLLOWING MULTIPLE INJECTIONS IN ADULT SUBJECTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)

Registry ID

C0221002

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

PFIZER CANADA INC

Start date

2022-06-08

Last update

2018-02-13

Conditions

• FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)

Related clinical trials

• A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFECTS OF ORAL TRPC6 INHIBITOR BI 764198 TAKEN OVER A 104 WEEK TREATMENT PERIOD IN ADULT AND ADOLESCENT PARTICIPANTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (PFSGS) OR GENETIC FSGS RELATED TO TRPC6 GENE VARIANTS
• STUDY OF LOSMAPIMOD TO REDUCE PROTEINURIA IN CORTICOSTEROID OR CALCINEURIN INHIBITOR RESISTANT IDIOPATHIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)

View on source registry